RPRX vs. TAK: Royalty Pharma vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Royalty Pharma (RPRX) and Takeda Pharmaceutical (TAK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Royalty Pharma (RPRX) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Royalty Pharma (RPRX) has a non-negative beta of 0.36.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Royalty Pharma (RPRX) at 12.09% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for RPRX.

Royalty Pharma (RPRX) at 25.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both Royalty Pharma (RPRX) at 81.32% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Royalty Pharma (RPRX) at 5.06% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Royalty Pharma (RPRX) at 23.09% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Both Royalty Pharma (RPRX) at 1.29 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Royalty Pharma (RPRX) at 0.88 and Takeda Pharmaceutical (TAK) at 0.72 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Both Royalty Pharma (RPRX) at 1.37% and Takeda Pharmaceutical (TAK) at 953.28% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Royalty Pharma (RPRX) reports 60.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Royalty Pharma (RPRX) at 43.99 sits in the richer P/E ratio quartile, and Takeda Pharmaceutical (TAK) at 300.29 is richer still, above its industry range.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Royalty Pharma (RPRX) at 4.39 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics